Workflow
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
Boston ScientificBoston Scientific(US:BSX) ZACKSยท2025-05-08 14:00

Core Viewpoint - Boston Scientific (BSX) has been a highly searched stock recently, indicating potential investor interest and market activity [1] Earnings Estimate Revisions - For the current quarter, Boston Scientific is expected to report earnings of $0.72 per share, reflecting a year-over-year increase of +16.1% [5] - The Zacks Consensus Estimate for the current fiscal year is $2.91, indicating a year-over-year change of +15.9%, with a +2.2% revision over the last 30 days [5] - The consensus earnings estimate for the next fiscal year is $3.26, showing a change of +11.8% from the previous year, with a +0.9% revision over the past month [6] - Boston Scientific holds a Zacks Rank 2 (Buy), suggesting a favorable outlook based on recent earnings estimate changes [7] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $4.89 billion, indicating a year-over-year increase of +18.6% [11] - For the current fiscal year, the sales estimate is $19.49 billion, reflecting a change of +16.4%, while the next fiscal year's estimate is $21.55 billion, indicating a +10.6% change [11] Last Reported Results and Surprise History - In the last reported quarter, Boston Scientific achieved revenues of $4.66 billion, a year-over-year increase of +20.9%, and an EPS of $0.75 compared to $0.56 a year ago [12] - The company exceeded the Zacks Consensus Estimate for revenues by +2.31% and for EPS by +11.94% [12] - Boston Scientific has consistently beaten consensus EPS and revenue estimates over the past four quarters [13] Valuation - Boston Scientific is graded D on the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [17] - Valuation metrics such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for assessing whether the stock is overvalued, fairly valued, or undervalued [15][16] Bottom Line - The information presented suggests that Boston Scientific may outperform the broader market in the near term, supported by its Zacks Rank 2 [18]